Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment

Immune checkpoint inhibition with PD‐1/PD‐L1 blockade is a promising area in the field of anti‐cancer therapy. Although clinical data have revealed success of PD‐1/PD‐L1 blockade as monotherapy or in combination with CTLA‐4 or chemotherapy, the combination with radiotherapy could further boost anti‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Mudassar, Faiqa, Shen, Han, Cook, Kristina M, Hau, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RADIATION ONCOLOGY
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322583/
https://www.ncbi.nlm.nih.gov/pubmed/35466515
http://dx.doi.org/10.1111/1754-9485.13416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322583/
https://www.ncbi.nlm.nih.gov/pubmed/35466515
http://dx.doi.org/10.1111/1754-9485.13416

Ejemplares similares